Patients are the center of what we do, and the value of PROs is important. PROs are well accepted as secondary endpoints in several CV trials today, but how ready are these tools to be included as primary endpoints? Dr. Prodromos Anthopoulos from Cytokinetics, the industry chairperson of #ESCardioCRT meeting, reflects on the discussions. #clinicaltrials | European Society of Cardiology

MYQORZO approval for Obstructive Hypertrophic Cardiomyopathy